-
Innovation Ranking
NewInnovation Ranking – Fortune Brands Home & Security Inc
Fortune Brands Innovations Inc (Fortune Brands) is a manufacturer of home and security consumer products. It sells kitchen and bath cabinetry, plumbing and accessories, advanced material window products and entry door systems, and security and storage products. Fortune Brands serves kitchen and bath dealers, wholesale builders, professional remodelers, industrial and locksmith distributors, home centers, and retail outlets. The company’s major brands include Riobel, Perrin and Rowe, Shaws, Fypon, Master Lock, and Homecrest. It operates in South America, Europe, and Southeast...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Zibotentan/Forxiga
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Zibotentan/Forxiga report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Gilead Sciences Inc’s Seladelpar Lysine
Empower your strategies with our Net Present Value Model: Gilead Sciences Inc's Seladelpar Lysine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: GSK plc’s GSK-1070806
Empower your strategies with our Net Present Value Model: GSK plc's GSK-1070806 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Monopar Therapeutics Inc’s Camsirubicin
Empower your strategies with our Net Present Value Model: Monopar Therapeutics Inc's Camsirubicin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s (Borneol + Edaravone)
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's (Borneol + Edaravone) report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Novartis AG’s Batoprotafib
Empower your strategies with our Net Present Value Model: Novartis AG's Batoprotafib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Solbinsiran Sodium
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Solbinsiran Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Teva Pharmaceutical Industries Ltd’s Golimumab Biosimilar
Empower your strategies with our Net Present Value Model: Teva Pharmaceutical Industries Ltd's Golimumab Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.